Searched for
SUN PHARMA OUTLOOK
Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbookInvestor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Sensex rises 291 points, Nifty closes above 24,100; Tech Mahindra, Sun Pharma among top gainersIndian stock markets saw a positive start on Monday, with Sensex and Nifty inching up after Friday's dip. Tech Mahindra led the gains, whil...
- Reliance, financials and defence top investment picks as market leadership broadens: Rahul ShahReliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant ...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Geopolitical stability will decide market’s next move: Sandip SabharwalIndian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...
- Strong revenue growth fails to shield India Inc margins in March quarterCorporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...
- Buy, Sell or Hold: Citi maintains buy on Eicher Motors; Goldman Sachs retains buy on Max HealthcareBrokerages maintain a positive outlook on select large-cap pharmaceutical, automobile, and healthcare stocks, citing strong growth prospect...
- Margin pressure, slower growth outlook may cap upside for Sun Pharma stockSun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and...
- 6 pharma stocks that Bernstein sees up to 40% upside potential. Do you own any?Bernstein initiated coverage on six pharma stocks, expressing a positive outlook on the Indian healthcare sector driven by AI, innovation i...
- Bank Nifty near key resistance zone; breakout above 54,300 crucial: Ajit MishraIndian equity markets are consolidating within a narrow range, with Nifty struggling to break 24,000 and Bank Nifty showing relative streng...
- Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap playsIndian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- Selling at higher levels turns 23,800 into key barrier for Nifty: AnalystsBenchmark Nifty closed lower last week. Analysts anticipate continued range-bound trading for Nifty this week. Trading strategies suggest b...
- Stock Radar: Sun Pharma breaks out from falling trendline resistance to hit fresh 52-week high; time to buy?Sun Pharmaceutical Industries Ltd has broken out from a falling trendline resistance on weekly charts, hitting a fresh 52-week high. Expert...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Bullish on power, energy, and BFSI; cautious on IT amid weak earnings: Devarsh VakilHDFC Securities sees opportunity in India's recovering equity markets. The firm favors power and energy sectors, citing infrastructure grow...
- Sun Pharma deal structurally strong, debt the only overhang: Amit KhuranaMarket expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma's acquisition is seen as strategically ...
- Q2 preview: Sun Pharma may report flat to single-digit profit growthPrabhudas Lilladher expects Sun Pharma to report a 7.1 per cent increase in net profit from a year ago, while it believes net sales may hav...
Load More
